Introduction: The modern ophthalmology trends are changing rapidly every day with the introduction of much newer studies and research. Numerous anti-vascular endothelial growth factors (VEGF) are utilized as the mainstay in the treatment of intraocular vascular pathologies. The rationale of this study is to add to the literature regarding the safety and efficacy profile of the ziv-aflibercept as there is insubstantial data in patients with intraocular vascular pathologies being treated with this injection with prime focus on the complications of the injection. Materials and Methods: A prospective observational study was conducted at Opthalmology Department, Lahore General Hospital, Lahore between 14 August 2018 and 23 December 2019. Patients with choroidal and retinal vascular diseases like diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO) who had no active infection of eye and had no history of myocardial infarction or cerebrovascular accident were added in this study. Results: Best-corrected visual acuity was significantly improved at 4, 8, and 12 weeks as compared to the baseline (p < 0.05). At 12 weeks there was statistically significant difference in BCVA changes. Central macular thickness was notably decreased in each 4-week interval comparatively to the baseline values (p < 0.05). At 24 weeks follow-up, BCVA and CMT showed notable improvement (p < 0.05). Conclusion: The use of ziv-aflibercept injection via intravitreal route under aseptic conditions for choroidal and retinal vascular diseases is effective as well as safe with mild and treatable ocular side effects.
References
[1]
Andrade, G., de Oliveira Dias, J., Maia, A., Farah, M., Meyer, C. and Rodrigues, E. (2018) Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes. Ophthalmic Surgery, Lasers and Imaging Retina, 49, 245-250. https://doi.org/10.3928/23258160-20180329-06
[2]
Andrade, G.C., Dias, J.R., Maia, A., et al. (2016) Intravitreal Injections of Ziv-Aflibercept for Diabetic Macular Edema. Retina, 36, 1640-1645. https://doi.org/10.1097/IAE.0000000000001000
[3]
Ashraf, M., Souka, A.A., El Kayal, H., El Manhaly, M. and Abdallah, M.H. (2016) Three-Month Outcomes of Ziv-Aflibercept in the Treatment of Diabetic Macular Oedema. Actaophthalmologica, 94, e669. https://doi.org/10.1111/aos.13111
[4]
McCannel, C.A. (2011) Meta-Analysis of Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. Retina, 31, 654-661. https://doi.org/10.1097/IAE.0b013e31820a67e4
[5]
Mezad-Koursh, D., Goldstein, M., Heilwail, G., Zayit-Soudry, S., Loewenstein, A. and Barak, A. (2010) Clinical Characteristics of Endophthalmitis after an Injection of Intravitreal Anti-Vascular Endothelial Growth Factor. Retina, 30, 1051-1057. https://doi.org/10.1097/IAE.0b013e3181cd47ed
[6]
Falavarjani, K. and Nguyen, Q.D. (2013) Adverse Events and Complications Associated with Intravitreal Injection of Anti-VEGF Agents: A Review of Literature. Eye, 27, 787-794. https://doi.org/10.1038/eye.2013.107
[7]
Singh, S.R., Stewart, M.W., Chattannavar, G., et al. (2019) Safety of 5914 Intravitreal Ziv-Aflibercept Injections. British Journal of Ophthalmology, 103, 805-810. https://doi.org/10.1136/bjophthalmol-2018-312453
[8]
Baghi, A., Bonyadi, M.H., Ramezani, A., et al. (2017) Two Doses of Intravitreal Ziv-Aflibercept versus Bevacizumab in Treatment of Diabetic Macular Edema: A Three-Armed, Double-Blind Randomized Trial. Ophthalmology Retina, 1, 103-110. https://doi.org/10.1016/j.oret.2016.08.007
[9]
Bakri, S.J., Pulido, J.S., McCannel, C.A., Hodge, D.O., Diehl, N. and Hillemeier, J. (2009) Immediate Intraocular Pressure Changes Following Intravitreal Injections of Triamcinolone, Pegaptanib, and Bevacizumab. Eye, 23, 181-185. https://doi.org/10.1038/sj.eye.6702938
[10]
Browning, D., Kaiser, P., Rosenfeld, P. and Stewart, M. (2012) Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition? American Journal of Ophthalmology, 154, 222-226. https://doi.org/10.1016/j.ajo.2012.04.020
[11]
Chhablani, J. (2015) Intravitreal Ziv-Aflibercept for Recurrent Macular Edema Secondary to Central Retinal Venous Occlusion. Indian Journal of Ophthalmology, 63, 469-470. https://doi.org/10.4103/0301-4738.159909
[12]
De Oliveira Dias, J.R., de Andrade, G.C., Kniggendorf, V.F., et al. (2019) Intravitreal Ziv-Aflibercept for Neovascular Age-Related Macular Degeneration: 52-Week Results. Retina, 39, 648-655. https://doi.org/10.1097/IAE.0000000000002001
[13]
De Oliveira Dias, J.R., de Andrade, G.C., Novais, E.A., Farah, M.E. and Rodrigues, E.B. (2016) Fusion Proteins for Treatment of Retinal Diseases: Aflibercept, Ziv-Aflibercept, and Conbercept. International Journal of Retina and Vitreous, 2, Article No. 3. https://doi.org/10.1186/s40942-016-0026-y
[14]
De Oliveira Dias, J.R., Xavier, C.O., Maia, A., et al. (2015) Intravitreal Injection of Ziv-Aflibercept in Patient with Refractory Age-Related Macular Degeneration. Ophthalmic Surgery, Lasers and Imaging Retina, 46, 91-94. https://doi.org/10.3928/23258160-20150101-17
[15]
Dervenis, N., Mikropoulou, A.M., Tranos, P. and Dervenis, P. (2017) Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges. Advances in Therapy, 34, 1270-1282. https://doi.org/10.1007/s12325-017-0548-1
[16]
Eldeeb, M., Chan, E.W., Dedhia, C.J., Mansour, A. and Chhablani, J. (2017) One-Year Outcomes of Ziv-Aflibercept for Macular Edema in Central Retinal Vein Occlusion. American Journal of Ophthalmology Case Reports, 8, 58-61. https://doi.org/10.1016/j.ajoc.2017.10.011
[17]
Good, T.J., Kimura, A.E., Mandava, N. and Kahook, M.Y. (2011) Sustained Elevation of Intraocular Pressure after Intravitreal Injections of Anti-VEGF Agents. British Journal of Ophthalmology, 95, 1111-1114. https://doi.org/10.1136/bjo.2010.180729
